Prostate Cancer Pathology: Recent Advances and Future Perspectives
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 67
Special Issue Editor
Interests: prostate cancer; anatomy; pathology; cell plasticity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent decades, dramatic changes in the diagnosis and management of prostate cancer have occurred. However, the rise in newly diagnosed cases (especially in younger men) mandates a more accurate pathological diagnosis that will facilitate the distinction of indolent cancers and save patients from unnecessary morbid interventions. Moreover, in the era of precision medicine, molecular pathology techniques and advances allow for more patient-centered and tailored management. However, the clinical and biological heterogeneity of prostate cancer is responsible for ongoing controversies in the pathological evaluation of the disease, ranging from the interpretation of initial biopsies and the reliability of the Gleason scoring system to the controversial utility of emerging biomarkers in the clinical setting.
The aim of this Special Issue is to present recent advances in the pathological evaluation, interpretation, and reporting of prostate carcinoma. Both original articles and interesting reviews are welcome to be submitted to this Special Issue to shed light on the continuously evolving landscape of the pathology of prostate cancer and its importance in precise clinical management.
Prof. Dr. Kostis Gyftopoulos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- pathology
- digital pathology
- Gleason grading
- molecular biomarkers
- precision medicine
- molecular pathology
- molecular profiling
- therapy resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
